



## Convertible note process update

**Sydney, 18 December 2024:** At the AGM held on 18 November 2024, Noxopharm's shareholders approved the issue of a convertible note to 4F Investments Pty Ltd, an associated entity of Fred Bart (a Noxopharm director) for a face value of up to \$1.25 million.

As disclosed in the notice of meeting, this convertible note was not to be funded until 2025.

To meet the requirements of ASX listing rule 10.13.5, these securities (convertible notes) need to be issued within 30 days of shareholder approval. As the note is not being funded within the prescribed 30-day period as required under listing rule 10.13.5, Noxopharm is not able to issue these convertible notes until funding is received from 4F Investments.

4F Investments intends to participate in this convertible note, and shareholder approval will be re-sought prior to the funding and subsequent issue of this note.

**-ENDS-**

### About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US registered, Australia based Nyrada Inc (ASX: NYR), a drug discovery and development company specialising in novel small molecule therapies.

To learn more, please visit: [noxopharm.com](https://noxopharm.com)

#### Investor, Corporate & Media enquiries:

Julian Elliott

M: 0425 840 071

E: [julian.elliott@noxopharm.com](mailto:julian.elliott@noxopharm.com)

#### Company Secretary:

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

*Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.*

---

### Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will"



or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.